Search research articles
Contact Us
Filters
Showing results (11-20 of 57) with videos related to
Page
of 6
Sort By:
British Journal of Pharmacology
|
April 1, 1997
Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
Y P Maneuf, J M Brotchie
European Journal of Neurology
|
December 5, 2002
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy
S L Nicholson, J M Brotchie
Neuropharmacology
|
February 12, 2022
Special Issue on new therapeutic approaches to Parkinson disease
S H Fox, J M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society
|
December 5, 2000
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease
S H Fox, J M Brotchie
British Journal of Pharmacology
|
December 22, 1999
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat
M P Hill, J M Brotchie
Journal of Neural Transmission (Vienna, Austria : 1996)
|
December 23, 2004
Levodopa-induced dyskinesia in Parkinson's disease
J M Brotchie, J Lee, K Venderova
Experimental Neurology
|
March 11, 1999
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
B Henry, A R Crossman, J M Brotchie
Nature Reviews. Neuroscience
|
August 3, 2001
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, J M Brotchie, C E Gross
Experimental Neurology
|
June 6, 1998
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
S H Fox, B Moser, J M Brotchie
Experimental Neurology
|
June 26, 1998
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
B Henry, A R Crossman, J M Brotchie
Page
of 6
Search research articles
Search
Showing results (11-20 of 57) with videos related to
Sort By:
Page
of 6
British Journal of Pharmacology
|
April 1, 1997
Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
Y P Maneuf, J M Brotchie
European Journal of Neurology
|
December 5, 2002
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy
S L Nicholson, J M Brotchie
Neuropharmacology
|
February 12, 2022
Special Issue on new therapeutic approaches to Parkinson disease
S H Fox, J M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society
|
December 5, 2000
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease
S H Fox, J M Brotchie
British Journal of Pharmacology
|
December 22, 1999
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat
M P Hill, J M Brotchie
Journal of Neural Transmission (Vienna, Austria : 1996)
|
December 23, 2004
Levodopa-induced dyskinesia in Parkinson's disease
J M Brotchie, J Lee, K Venderova
Experimental Neurology
|
March 11, 1999
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
B Henry, A R Crossman, J M Brotchie
Nature Reviews. Neuroscience
|
August 3, 2001
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, J M Brotchie, C E Gross
Experimental Neurology
|
June 6, 1998
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
S H Fox, B Moser, J M Brotchie
Experimental Neurology
|
June 26, 1998
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
B Henry, A R Crossman, J M Brotchie
Page
of 6